Revenio Group

Revenio's Q2 result fell short of our expectations due to a weak period in the core business. Visionix performed roughly as expected in its debut, and its integration appears to be progressing as planned.

At the Capital Markets Day, the company's key personnel will present an in-depth overview of Revenio's strategy.

Revenio's Q2 report also includes a one-month contribution from the Visionix acquisition.

The first FDA approval for the combination of the iCare imaging device and AI removes uncertainty and supports growth in device sales in the United States.

The strategic partnership can expand the availability of iCare devices in the United States.

The company aims for an EBITDA improvement of over 20 MEUR through Visionix synergies by the end of 2029.